BioPharmSignal logoBioPharmSignal

Biotech News

Kura Oncology Reports Second Quarter 2026 Financial Results

Kura Oncology (KURA)Kura OncologyEarnings

– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full

Related news

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

KURAKura Oncology2026-08-10 12:32 EST

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

View all latest news

Kura Oncology

Precision Oncology Company Kura Oncology develops and commercializes small-molecule therapies for genetically defined cancers. Its portfolio focuses on menin inhibition in hematologic malignancies and farnesyl-transferase inhibition in solid tumors. KOMZIFTI KOMZIFTI, or ziftomenib, is an FDA-approved oral menin inhibitor for adults with...

Recent company news

KURAKura Oncology2026-08-12 20:02 EST

Kura Oncology Reports Second Quarter 2026 Financial Results

KURAKura Oncology2026-08-10 12:32 EST

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

KURAKura Oncology2026-07-27 10:32 EST

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

Stock data

Close
11.28 USD
Market cap
796.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States